Chronic inhibition of farnesyl pyrophosphate synthase attenuates cardiac hypertrophy and fibrosis in spontaneously hypertensive rats

Biochemical Pharmacology

Volumn 79, Issue 3, 2010, Pages 399-406

  Li, Liang ^a   Chen, Guo Ping ^a   Yang, Yin ^a   Ye, Yang ^a   Yao, Lei ^a   Hu, Shen Jiang ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b Immunology Division   (China)

Author keywords

Alendronate; Cardiac hypertrophy; Farnesyl diphosphate synthase; Spontaneously hypertensive rat

Indexed keywords

ALENDRONIC ACID; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; COLLAGEN; GERANYLTRANSFERASE; HYDROXYPROLINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROCOLLAGEN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; LONG TERM CARE; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STRAIN DIFFERENCE; UPREGULATION; WISTAR KYOTO RAT;

ALENDRONATE; ANIMALS; CARDIOMEGALY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FIBROSIS; GERANYLTRANSTRANSFERASE; HYPERTENSION; MALE; RATS; RATS, INBRED SHR; RATS, INBRED WKY;

EID: 70449642351     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.08.033     Document Type: Article

References (55)

1. Berk B.C., Fujiwara K., and Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 117 (2007) 568-575
2. Casale P.N., Devereux R.B., Milner M., Zullo G., Harshfield G.A., Pickering T.G., et al. Value of echocardiographic assessment of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 105 (1986) 173-178
3. Koren M.J., Devereux R.B., Casale P.N., Savage D.D., and Laragh J.H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114 (1991) 345-352
4. Clerk A., Bogoyevitch M.A., Anderson M.B., and Sugden P.H. Differential activation of protein kinase C isoforms by endothelin-1 and phenylephrine and subsequent stimulation of p42 and p44 mitogen-activated protein kinases in ventricular myocytes cultured from neonatal rat hearts. J Biol Chem 269 (1994) 32848-32857
5. Bueno O.F., De Windt L.J., Tymitz K.M., Witt S.A., Kimball T.R., Klevitsky R., et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19 (2000) 6341-6350
6. Bueno O.F., De Windt L.J., Lim H.W., Tymitz K.M., Witt S.A., Kimball T.R., et al. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ Res 88 (2001) 88-96
7. Euler-Taimor G., and Heger J. The complex pattern of SMAD signaling in the cardiovascular system. Cardiovasc Res 69 (2006) 15-25
8. Khan R., and Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 118 (2006) 10-24
9. Aoki H., Richmond M., Izumo S., and Sadoshima J. Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro. Biochem J 347 (2000) 275-284
10. Mulder K.M. Role of Ras and Mapks in TGF beta signaling. Cytokine Growth Factor Rev 11 (2000) 23-25
11. Ishikawa Y., Nishikimi T., Akimoto K., Ishimura K., Ono H., and Matsuoka H. Long-term administration of Rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension 47 (2006) 1075-1083
12. Hubchak S.C., Runyan C.E., Kreisberg J.I., and Schnaper H.W. Cytoskeletal rearrangement and signal transduction in TGF-β1-stimulated mesangial cell collagen accumulation. J Am Soc Nephrol 14 (2003) 1969-1980
13. Roskoski Jr. R. Protein prenylation: a pivotal posttranslational process. Biochem Biophys Res Commun 303 (2003) 1-7
14. Casey P.J. Protein lipidation in cell signaling. Science 268 (1995) 221-225
15. Chen G.P., Yao L., Lu X., Li L., and Hu S.J. Tissue-specific effects of atorvastatin on 3-hydroxy-3-methylglutarylcoenzyme A reductase expression and activity in spontaneously hypertensive rats. Acta Pharmacol Sin 29 (2008) 1181-1186
16. Li L., Hu S.J., Dong H.T., Kang L., Chen N.Y., and Fang Y.Q. Alterations in gene expression of series key enzymes in mevalonic acid pathway detected by RNA array in spontaneously hypertensive rats. Chin J Pathophysiol 24 (2008) 54-59
17. Szkopińska A., and Płochocka D. Farnesyl diphosphate synthase; regulation of product specificity. Acta Biochim Pol 52 (2005) 45-55
18. Arai H., Nakao K., Saito Y., Morii N., Sugawara A., Yamada T., et al. Augmented expression of atrial natriuretic polypeptide gene in ventricles of spontaneously hypertensive rats (SHR) and SHR-stroke prone. Circ Res 62 (1988) 926-930
19. Boluyt M.O., Bing O.H., and Lakatta E.G. The aging spontaneously hypertensive rat as a model of the transition from stable compensated hypertrophy to heart failure. Eur Heart J 16 Suppl. N (1995) 19-30
20. Conrad C.H., Brooks W.W., Hayes J.A., Sen S., Robinson K.G., and Bing O.H. Myocardial fibrosis and stiffness with hypertrophy and heart failure in spontaneously hypertensive rat. Circulation 91 (1995) 161-170
21. Palmer B.M., Chen Z., Lachapelle R.R., Hendley E.D., and LeWinter M.M. Cardiomyocyte function associated with hyperactivity and/or hypertensive in genetic models of LV hypertrophy. Am J Physiol Heart Circ Physiol 290 (2006) H463-H473
22. Izumi Y., Kim S., Murakami T., Yamanaka S., and Iwao H. Cardiac mitogen-activated protein kinase activities are chronically increased in stroke-prone hypertensive rats. Hypertension 31 (1998) 50-56
23. Touyz R.M., He G., Mabrouk M.E., and Schiffrin E.L. p38 MAP kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY. Hypertension 37 (2001) 574-580
24. Zhai Y.S., Gao X.R., Wu Q.M., Peng L.Y., Lin J., and Zuo Z.Y. Fluvastatin decreases cardiac fibrosis possibly though regulation of TGF-β1/Smad 7 expression in the spontaneously hypertensive rats. Eur J Pharmacol 587 (2008) 196-203
25. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Mönkkönen J., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 (2000) 2961-2978
26. Roelofs A.J., Thompson K., Gordon S., and Rogers M.J. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 15 Suppl. 12 (2006) 6222-6230
27. Bergstrom J.D., Bostedor R.G., Masarachia P.J., Reszka A.A., and Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 373 (2000) 231-241
28. Kubota Y., Umegaki K., Kagota S., Tanaka N., Nakamura K., Kunitomo M., et al. Evaluation of blood pressure measured by tail-cuff methods (without heating) in spontaneously hypertensive rats. Biol Pharm Bull 29 (2006) 1756-1758
29. Sun Y.L., Hu S.J., Wang L.H., Hu Y., and Zhou J.Y. Effect of β-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. Chest 128 (2005) 1812-1821
30. Kang L., Ge C.J., and Hu S.J. Beneficial effect of atorvastatin on left ventricular remodeling in spontaneously hypertensive rats. Pharmacology 80 (2007) 120-126
31. Cuspidi C., Ciulla M., and Zanchetti A. Hypertensive myocardial fibrosis. Nephrol Dial Transplant 21 (2006) 20-23
32. Sugden P.H. Signaling in myocardial hypertrophy: life after calcineurin?. Circ Res 84 (1999) 633-646
33. Sugden P.H., and Clerk A. Stress-responsive mitogen-activated protein kinases (C-jun n-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 83 (1998) 345-352
34. Border W.A., and Nobel N.A. Transforming growth factor-β in tissue fibrosis. N Engl J Med 331 (1994) 1286-1292
35. Pauschinger M., Knopf D., Petschauer S., Doerner A., Poller W., Schwimmbeck P.L., et al. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 99 (1999) 2750-2756
36. Tomita H., Egashira K., Ohara Y., Takemoto M., Koyanaqi M., Katoh M., et al. Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 32 (1998) 273-279
37. Grotendorst G.R. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 8 (1997) 171-179
38. Oemar B.S., Werner A., Garnier J.M., Do D.D., Godoy N., Nauck M., et al. Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation 95 (1997) 831-839
39. Ohnishi H., Oka T., Kusachi S., Nakanishi T., Takeda K., Nakahama M., et al. Increased expression of connective tissue growth factor in the infarct zone of experimentally induced myocardial infarction in rats. J Mol Cell Cardiol 30 (1998) 2411-2422
40. Thorburn A., Thorburn J., Chen S.Y., Powers S., Shubeita H.E., Feramisco J.R., et al. HRas-dependent pathways can activate morphological an genetic markers of cardiac muscle cell hypertrophy. J Biol Chem 268 (1993) 2244-2249
41. Sah V.P., Hoshijima M., Chien K.R., and Brown J.H. Rho is required for Gαq and α1-adrenergic receptor signaling in cardiomyocytes, dissociation of Ras and Rho pathway. J Biol Chem 271 (1996) 31185-31190
42. Moriki N., Ito M., Seko T., Kureishi Y., Okamoto R., Nakakuki T., et al. RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Hypertens Res 27 (2004) 263-270
43. Seko T., Ito M., Kureishi Y., Okamato R., Moriki N., Onishi K., et al. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res 92 (2003) 411-418
44. Laboureau J., Dubertret L., Lebreton-De Coster C., and Coulomb B. ERK activation by mechanical strain is regulated by the small G proteins rac-1 and rhoA. Exp Dermatol 13 (2004) 70-77
45. Aikawa R., Komuro I., Yamazaki T., Zou Y.Z., Kudoh S., Zhu W.D., et al. Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes. Circ Res 84 (1999) 458-466
46. +/- haploinsufficient mice. Circulation 112 (2005) 2959-2965
47. Laufs U., Kilter H., Konkol C., Wassmann S., Böhm M., and Nickenig G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Circ Res 53 (2002) 911-920
48. Tamura T., Said S., Harris J., Lu W.Y., and Gerdes A.M. Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system. Circulation 102 (2000) 253-259
49. Lee T.M., Lin M.S., Tsai C.H., and Chang N.C. Effect of pravastatin on left ventricular mass in the two-kidney, one-clip hypertensive rats. Am J Physiol Heart Circ Physiol 291 (2006) H2705-H2713
50. Susic D., Varaqic J., Ahn J., Slama M., and Frohlich E.D. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 42 (2003) 1091-1097
51. Allen M.R., and Burr D.B. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 22 11 (2007) 1759-1765
52. Pytlik M., Kaczmarczyk-Sedlak I., Sliwinski L., Janiec W., and Rymkiewicz I. Effect of concurrent administration of alendronate sodium and retinal on development of changes in histomorphometric parameters of bones induced by ovariectomy in rats. Pol J Pharmacol 56 5 (2004) 571-579
53. Anastasilakis A.D., Goulis D.G., Kita M., and Avramidis A. Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases. Hormones (Athens) 6 3 (2007) 233-241
54. Finkelstein J.S., Leder B.Z., Burnett S.M., Wyland J.J., Lee H., de la Paz A.V., et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 91 8 (2006) 2882-2887
55. Peter C., and Rodan G.A. Preclinical safety profile of alendronate. Int J Clin Pract Suppl 101 (1999) 3-8